. . . . . . . "[These pathways modulate cellular proliferation, adhesion, angiogenesis, migration, and survival.(3) Anti-EGFR targeted antibodies, such as cetuximab and panitumumab, have shown response and disease stabilization rates of approximately 10% and 30%, respectively, when administered as monotherapy in CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:11+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .